Soleno Therapeutics Provides Update on DCCR for the Treatment of PWS
FDA agrees to review additional data to determine adequacy for submission of NDA Soleno Therapeutics, Inc. provided an update on Tuesday, July 7, 2021 following a recent interaction with the FDA regarding the development of DCCR, a potential treatment for PWS. According to Soleno Therapeutics, on July 2, 2021 they received news from The FDA,...
FDA Grants Priority Review for Levo Therapeuticsโ New Drug Application for LV-101 (Intranasal Carbetocin) for the Treatment of Prader-Willi Syndrome
Read Levo Therapeutic, Inc.’s Full Article HERE. CHICAGO, IL, July 6, 2021 (Newswire.com) โ Levo Therapeutics, Inc., a biotechnology company dedicated to using genetic insights to advance treatments for Prader-Willi syndrome (PWS) and related disorders, announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for review and...
PWSA | USA and FPWR Share Community Update on FDA Patient Listening Session
On June 17, 2021, PWSA | USA and FPWR held a Patient Listening Session with the FDA to share our communityโs experiences related to Prader-Willi syndrome (PWS).ย The purpose of this meeting was to promote dialogue between the FDA and members of the PWS patient community to ensure the FDA has a full understanding of...
Dr. Moris Angulo, MD Opens New Clinic in New York
We are pleased to announce that Dr. Moris Angulo M.D. has opened a new clinic, located in Bablyon, NY, and is accepting patients. Location: Center for Pediatric Specialty Care, 655 Deer Park Avenue, Babylon, NY 11702 To schedule an appointment, call 631-321-2100 ——————————————– Moris A. Angulo, M.D., was born in El Salvador, Central Amรฉrica and...